Compare compounds

Vials

10 mg

Dosing data

Lab reference — not listed

PT-141 (bremelanotide) is a melanocortin receptor agonist, acting mainly on central MC4 receptors involved in sexual motivation.

• RECONNECT (two phase 3 trials, 1,267 premenopausal women with hypoactive sexual desire disorder): significant increases in desire and reductions in related distress vs placebo.
• Integrated safety data (1,247 women): nausea was the main reason for stopping treatment.

• FDA-approved (as Vyleesi) only for hypoactive sexual desire disorder in premenopausal women; research-grade material is not that product.
• Most common adverse events: nausea (40.0% vs 1.3%), flushing (20.3% vs 1.3%) and headache (11.3% vs 1.9%). Small, transient blood-pressure increases were seen.
• Focal hyperpigmentation was rare at labelled use but affected more than a third of participants after up to 16 consecutive daily administrations.

2 references · view